The potential utility of B cell-directed biologic therapy in autoimmune diseases

Rheumatology International

Volumn 28, Issue 3, 2008, Pages 205-215

  Arkfeld, D G ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

B lymphocytes; Biologic therapies; CD20; Lupus; Rituximab; Sj gren's syndrome; Thrombocytopenic purpura; Vasculitis

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CD20 ANTIGEN; CETIRIZINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXCHLORPHENIRAMINE; HYDROCORTISONE; IMMUNOGLOBULIN; MEPREDNISONE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOLOGICAL THERAPY; CHICKENPOX; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; COLD AGGLUTININ SYNDROME; CRYOGLOBULINEMIA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; HEART DISEASE; HUMAN; HYPONATREMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; JUVENILE RHEUMATOID ARTHRITIS; MULTIPLE SCLEROSIS; MYOSITIS; PLASMA TRANSFUSION; PREMEDICATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SEPSIS; SERUM SICKNESS LIKE REACTION; SIDE EFFECT; SJOEGREN SYNDROME; STREPTOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VASCULITIS; VIRUS PNEUMONIA; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PURPURA, THROMBOCYTOPENIC; SJOGREN'S SYNDROME; TREATMENT OUTCOME; VASCULITIS;

EID: 37249092920     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0471-x     Document Type: Review

References (103)

1. Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL (2006) Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis 65:1117-1118
2. Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL (2005) Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 64:1087-1088
3. Ahmed A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME et al (2004) Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 77:171-176
4. Ames PR, Tommasino C, Fossati G, Scenna G, Brancaccio V, Ferrara F (2007) Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol 86:227-228
5. Anandacoomarasamy A, Gibson J, McGill N (2006) 'Cure' of life-threatening antiphospholipid syndrome with rituximab. Intern Med J 36:474-475
6. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J et al (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459
7. Aranda-Pereira P, Melendez-Mercado C, Jaimes-Hernandez J (2007) Rituximab, alternative treatment in refractory idiopathic inflammatory myopathies. Ann Rheum Dis 66(Suppl. II):199 [Abstract No. THU0236]
8. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K et al (2006) Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853-858
9. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C et al (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25-33
10. Bar-Or A, Calabresi P, Arnold D, Markowitz C, Shafer S, Kasper L et al (2007) A Phase I, open-label, multicenter study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS). In: American Academy of Neurology 59th Annual Meeting; Boston, April 28-May 5, 2007 [Abstract No. S.02.001]
11. Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H et al (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103:2925-2928
12. Blom M, van den Hoogen FH, Voermans NC, van Riel PL, Preijers FW, van Engelen BG et al (2007) Successful treatment with rituximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 66(Suppl. II):202 [Abstract No. THU0245]
13. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB et al (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78:275-280
14. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L (2007) Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 25:S23-S27
15. Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ et al (2006) Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 7:140-144
16. Chiappetta N, Steier J, Gruber B (2005) Rituximab in the treatment of refractory dermatomyositis. J Clin Rheum 11:264-266
17. Chow KV, Carroll R, Branley P, Nicholls K, Becker G, Hogan C (2007) Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Intern Med J 37:329-332
18. Chowdhury F, Lawrence K, Baglin T, Perry D (2006) Rituximab failure in a patient with allo-FVIII inhibitor. Br J Haematol 135:412
19. Christopher-Stine L, Plotz PH (2004) Myositis: an update on pathogenesis. Curr Opin Rheumatol 16:700-706
20. Clayton AR, Savage CO (2003) Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis. Clin Exp Immunol 132:174-179
21. Cohen SB (2005) B-cell depletion for rheumatic diseases: where are we? MedGenMed 7:72
22. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S et al (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232-239
23. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180:63-70
24. Dass S, Bowman S, Vital EM, Ikeda K, Pease CT, Emery P (2007) Safety and efficacy of rituximab in Sjögren's syndrome: results of a randomised, placebo-controlled trial. Ann Rheum Dis 66(Suppl. II):70 [Abstract No. OP0061]
25. de Vita S, Quartuccio L (2006) Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 5:443-448
26. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S et al (2007) Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57:310-317
27. Ding C, Jones G (2006) Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline). Curr Opin Investig Drugs 7:464-472
28. Dinh HV, McCormack C, Hall S, Prince HM (2007) Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 56:148-153
29. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8:R74
30. Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40:205-211
31. Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6:394-403
32. Efthimiou P, Paik PK, Bielory L (2006) Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 65:564-572
33. Eisenberg R, Albert D (2006) B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2:20-27
34. Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540-548
35. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R et al (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932-1937
36. Finsterer J (2005) Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand 112:115-125
37. Fox RI (2005) Sjogren's syndrome. Lancet 366:321-331
38. Fox RI (2007) FDA alert for rituximab in patients with systemic lupus erythematosus. Medscape Rheumatol
39. Franchini M (2006) The antiphospholipid syndrome: an update. Clin Lab 52:11-17
40. Gillis JZ, Dall'Era M, Gross A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57:538-542
41. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R et al (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 15:289-302
42. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56:1263-1272
43. Hansen A, Lipsky PE, Dörner T (2005) Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17:558-565
44. Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R et al (2007) A Phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS). In: American Academy of Neurology 59th annual meeting, Boston, April 28-May 5, 2007 [Abstract No. S.12.003]
45. Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97:228-233
46. Ioannou Y, Isenberg DA (2002) Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 78:599-606
47. Kadar J, Petrovicz E (2004) Adult-onset Still's disease. Best Pract Res Clin Rheumatol 18:663-676
48. Kalled SL (2006) Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 18:290-296
49. Kaushik VV, Reddy HV, Bucknall RC (2006) Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 65:1116-1117
50. Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262-268
51. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180-187
52. Koukoulaki M, Smith KG, Jayne DR (2006) Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65:557-559
53. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 32:1369-1370
54. Langford CA (2003) Wegener's granulomatosis: current and upcoming therapies. Arthritis Res Ther 5:180-191
55. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44:1542-1545
56. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601-607
57. Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764-766
58. Looney RJ (2006) B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs 66:625-639
59. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580-2589
60. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195
61. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M (2004) Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 77:303-310
62. Mok CC, Ho LY, To CH (2007) Rituximab for refractory polymyositis: an open-label pilot study. Ann Rheum Dis 66(Suppl II):216 [Abstract No. THU0292]
63. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62:258-264
64. Ng KP, Cambridge G, Leandro M, Edwards JC, Ehrenstein MR, Isenberg DA (2007) B cell depletion therapy in patients with systemic lupus erythematosus: long term follow up and predictors of response. Ann Rheum Dis 66(Suppl. II):56 [Abstract No. OP0020]
65. Norton A, Roberts I (2006) Management of Evans syndrome. Br J Haematol 132:125-137
66. Noss EH, Hausner-Sypek DL, Weinblatt ME (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33:1021-1026
67. Oliveira B, Arkfeld DG, Weitz IC, Shinada S, Ehresmann G (2007) Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. J Clin Rheumatol 13:89-91
68. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G (2005) Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 34:229-232
69. Ozdogu H, Boga C, Kizilkilic E, Yeral M, Kozanoglu I, Karatas M (2007) A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke. J Thromb Thrombolysis 23:147-150
70. Patino W, Sarode R (2007) Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J Clin Apher 22:17-20
71. Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, Rodriguez L, Casado M et al (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 85:400-406
72. Perrotta AL (2006) Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost 12:97-100
73. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52:2740-2750
74. Reddy PS, Deauna-Limayo D, Cook JD, Ganguly SS, Blecke C, Bodensteiner DC et al (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84:232-235
75. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C et al (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106:1262-1267
76. Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B (2006) Successful treatment of a patient with primary Sjogren's syndrome with Rituximab. Clin Rheumatol 25:891-894
77. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA (2006) Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33:355-357
78. Sabahi R, Anolik JH (2006) B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66:1933-1948
79. Sánchez-Cano D, Callejas-Rubio JL, Rios-Fernández R, Ortego-Centeno N (2007) Use of rituximab in Wegener's granulomatosis: comment on the article by Wong. Nephrol Dial Transplant 22:958-959
80. Sansonno D, de Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818-3826
81. Schollkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE et al (2006) Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 47:253-260
82. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136:451-461
83. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M et al (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66:351-357
84. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A et al (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52:501-513
85. Smith KG, Jones RB, Burns SM, Jayne DR (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970-2982
86. Sperr WR, Lechner K, Pabinger I (2007) Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 92:66-71
87. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952-957
88. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45:1432-1436
89. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM et al (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8:R129
90. Steinfeld SD, Youinou P (2006) Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther 6:943-949
91. Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M et al (2007) Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 46:409-414
92. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470-475
93. Touma Z, Sayad J, Arayssi T (2006) Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol 35:323-325
94. Trappe R, Loew A, Thuss-Patience P, Dorken B, Riess H (2006) Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 85:134-135
95. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C et al (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83
96. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947
97. Wiik A (2003) Autoantibodies in vasculitis. Arthritis Res Ther 5:147-152
98. Wong CF (2007) Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol Dial Transplant 22:32-36
99. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 124:787-795
100. Youinou P, Renaudineau Y (2004) The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res 114:363-369
101. Zaja F, de Vita S, Mazzaro C, Sacco S, Damiani D, de Marchi G et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827-3834
102. Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V et al (2006) Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 34:571-572
103. Zhang Z, Bridges SL Jr (2001) Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am 27:335-353